AVI Biopharma Adds Chief Scientist

Xconomy Seattle — 

AVI Biopharma (NASDAQ: AVII), the Bothell, WA-based developer of RNA-based therapies, said today it has hired Peter Linsley as its chief scientific officer. Linsley, 59, had previously been the chief scientist at San Diego-based Regulus Therapeutics, a company formed by Alnylam Pharmaceuticals and Isis Pharmaceuticals to develop microRNA treatments.